Get started
Author

Ana Mato-Berciano

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
2019 · Guillem Pascual-Pasto, Miriam Bazan-Peregrino, et al. · Science Translational Medicine · 120
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
2021 · Miriam Bazan-Peregrino, Rocio Garcia-Carbonero, et al. · Journal for ImmunoTherapy of Cancer · 115
PDF
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
2022 · Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, et al. · Journal for ImmunoTherapy of Cancer · 105
PDF
Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses
2020 · Giulia Raimondi, Ana Mato-Berciano, et al. · EBioMedicine · 69
PDF
Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation
2021 · Martí Farrera-Sal, Rafael Moreno, et al. · Molecular Therapy — Oncolytics · 36
PDF
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11
2021 · Ana Mato-Berciano, Sara Morgado, et al. · Journal of Controlled Release · 29
A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel
2017 · Ana Mato-Berciano, Giulia Raimondi, et al. · Oncotarget · 20
PDF
Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial
2019 · R. Garcia-Carbonero, M. Gil Martín, et al. · Annals of Oncology · 13
uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors
2013 · Luciano Sobrevals, Ana Mato-Berciano, et al. · Stem Cell Research · 13
PDF
Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems
2011 · Cristina Fillat, Anabel Jose, et al. · Cancers · 12
PDF
AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation
2015 · Maria Victoria Maliandi, Ana Mato-Berciano, et al. · Molecular Cancer · 9
PDF
Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
2014 · Cristina Fillat, Maria Maliandi, et al. · Current Pharmaceutical Design · 8
Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids
2021 · Silvia Pascual-Sabater, Giulia Raimondi, et al. · STAR Protocols · 7
PDF
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al. · Clinical Cancer Research · 5
Controlling Adenoviral Replication to Induce Oncolytic Efficacy~!2009-11-11~!2010-01-02~!2010-05-26~!
2010 · Cristina Fillat, Anabel Jose, et al. · The Open Gene Therapy Journal · 4
Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
2019 · M. Hidalgo, M. Bazan-Peregrino, et al. · Annals of Oncology · 2
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial
2026 · Rocio Garcia-Carbonero, Roberto Pazo Cid, et al. · Nature Medicine
Table S5 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S3 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S11 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S10 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S7 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S4 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Works count: 46
Citation count: 567
H-index: 10
I10-index: 10
Year
Topic
Type